Quick facts
- The Ministry of Health has announced that the 2025/26 maternal, infant, and high-risk children RSV prevention program will come to an end on April 17, 2026.
- Doses of the monoclonal antibody (Beyfortus) and the maternal vaccine (Abrysvo) should no longer be administered to infants, children, or pregnant women after this date.
- The 2025/26 older adult RSV prevention program will continue throughout the spring and summer of 2026 (i.e. year-round) for eligible individuals (external link).
Key messages for healthcare providers
Infants and High-Risk Children RSV Prevention Program
- All remaining non-expired inventory held at healthcare premises should be stored under appropriate cold chain for use during the next RSV season.
- If maternal, infant or high-risk doses are required after April 17, 2026, for exceptional use, please contact Public Health by calling 311.
Older Adult RSV Prevention Program
- The 2025/26 older adult RSV prevention program that was initiated last fall continues throughout the year for eligible individuals (external link).
- The RSV vaccine has demonstrated multi-year protection and is authorized as a single dose (i.e., no boosters). Therefore, the vaccine can be administered outside the RSV season.
- To order RSV products, fax a completed RSV Product Order Form (PDF file) to 905-465-3403.
Additional resources
Respiratory Syncytial Virus (RSV) prevention programs (external link), Ontario Ministry of Health